Latest Patents News

Critical Resources Limited has secured $1.6 million through a share placement to fund exploration across multiple jurisdictions and advance early-stage battery and thermal management technologies.

Anson Resources has lodged two US patent applications for a novel chemical-free technology that removes iron from lithium-rich brines, potentially cutting costs and environmental impact in its Direct Lithium Extraction process.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

Perpetual Resources has digitised and reviewed 42 historical drill holes from its Nevada Scheelite tungsten project, identifying 22 with significant tungsten grades, underpinning plans for modern validation and 3D geological modelling.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Senetas Corporation reported a 4.7% rise in revenue to $20.2 million for FY2026, achieving a strong $4.4 million operating cash flow turnaround. The company advanced its AI governance platform while maintaining a robust sales pipeline and capital management strategy.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.